Long-Term Real-World Experience with Safinamide in Patients with Parkinson’s Disease

Long-Term Real-World Experience with Safinamide in Patients with Parkinson’s Disease

Introduction: Randomized clinical trials should be complemented with data from real-world studies. We report our long-term experience with safinamide in a movement disorders unit. Methods: This retrospective study included patients with Parkinson’s disease (PD) treated with safinamide in our unit fr...

Full description

Saved in:
Bibliographic Details
Main Authors: Anna Planas-Ballvé, Núria Caballol Pons, Alejandro Peral Quirós, Isabel Gómez Ruiz, Marta Balagué Marmaña, Alexander J. Velázquez Ballester, Dolors Lozano Moreno, Asunción Ávila Rivera
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Brain Sciences
Subjects:
Parkinson’s disease
safinamide
MAO-B inhibitor
real-world evidence
discontinuation rate
motor symptoms
Online Access:https://www.mdpi.com/2076-3425/14/12/1238
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction: Randomized clinical trials should be complemented with data from real-world studies. We report our long-term experience with safinamide in a movement disorders unit. Methods: This retrospective study included patients with Parkinson’s disease (PD) treated with safinamide in our unit from February 2016 to May 2022 under routine clinical practice. Assessments included the Hoehn and Yahr (HY) stage, unified Parkinson’s disease rating scale (UPDRS) part III score, levodopa equivalent daily dose (LEDD), LEDD for dopamine agonists, and safinamide treatment discontinuation. Results: We included 180 patients with a median age of 74 years (IQR 11), and the majority (90.6%) had an HY stage of ≤2. After a median follow-up of 40 months (IQR 34), 14 patients discontinued treatment with safinamide (7.8%, 95% CI 4.7 to 12.6). Among the 166 patients who remained on safinamide, the UPDRS III score was stable (10 (IQR 9) vs. 9 (IQR 13), <i>p</i> = 0.455). The LEDD significantly increased from a median of 300 mg to 500 mg (<i>p</i> < 0.001), whereas the LEDD for dopamine agonists did not significantly increase. A subgroup of 89 patients who did not require dopamine agonists during follow-up showed stable UPDRS III score (10 (IQR 7) vs. 9 (IQR 14); <i>p</i> = 0.923), with a significant LEDD increase (300 mg to 400 mg, <i>p</i> < 0.001). Conclusions: Our results support the long-term effectiveness and tolerability of safinamide in patients with PD in clinical practice.
ISSN:2076-3425

Similar Items